Published in Osteoporos Int on October 16, 2007
Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int (2010) 1.18
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab (2009) 0.99
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int (2010) 0.97
Osteoanabolics. Indian J Endocrinol Metab (2012) 0.92
Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab (2010) 0.80
Osteoporosis Treatment: When to Discontinue and When to Re-start. Bone Res (2013) 0.76
Teriparatide: a novel means to ultimately achieve true regeneration!!! J Clin Diagn Res (2013) 0.75
The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75
Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int (2017) 0.75
Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate. Calcif Tissue Int (2017) 0.75
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol (2006) 2.03
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res (2005) 1.33
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res (2003) 1.29
Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int (2000) 1.12
Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res (2000) 1.05
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int (2004) 1.05
Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int (2000) 0.92
Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int (2005) 0.82
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2005) 0.78
Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone (1998) 0.78
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
The current and future market for veterinarians and veterinary medical services in the United States. J Am Vet Med Assoc (1999) 9.90
Finding protein similarities with nucleotide sequence databases. Methods Enzymol (1990) 6.63
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab (2001) 3.55
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int (2001) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem (1996) 3.26
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics (2000) 2.75
Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA (2001) 2.70
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature (1985) 2.15
Clonal rat parathyroid cell line expresses a parathyroid hormone-related peptide but not parathyroid hormone itself. Biochem Biophys Res Commun (1989) 2.15
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res (1998) 2.12
Selective inactivation of the transacylase components of the 2-oxo acid dehydrogenase multienzyme complexes of Escherichia coli. Biochem J (1976) 2.10
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res (1980) 1.89
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. Gut (1993) 1.83
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Parathyroid glands: combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology (2000) 1.80
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab (2013) 1.77
The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand (2006) 1.76
Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study. Osteoporos Int (2006) 1.75
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol (1990) 1.73
Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol (1998) 1.72
Acute physiological effects of exhaustive whole-body vibration exercise in man. Clin Physiol (2000) 1.72
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet (1997) 1.69
How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int (2010) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
A molecular-based magnet test for malaria. Am J Clin Pathol (1995) 1.65
Bone-muscle strength indices for the human lower leg. Bone (2000) 1.65
The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int (2007) 1.64
Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology (1998) 1.64
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet (1997) 1.64
Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med (1989) 1.64
Tumor-induced osteomalacia--unveiling a new hormone. N Engl J Med (1994) 1.61
Muscle triglyceride utilization during exercise: effect of training. J Appl Physiol (1985) (1986) 1.59
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc (1999) 1.58
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med (2005) 1.58
Meat consumption and risk of lung cancer: evidence from observational studies. Ann Oncol (2012) 1.57
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J (1988) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Linkage of structure at the proximal femur to chromosomes 3, 7, 8, and 19. J Bone Miner Res (2003) 1.55
Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone (2011) 1.55
Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact (2010) 1.53
Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium. Mutat Res (1976) 1.51
Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Regul Toxicol Pharmacol (1998) 1.51
The European Spine Phantom--a tool for standardization and quality control in spinal bone mineral measurements by DXA and QCT. Eur J Radiol (1995) 1.51
Oxygen uptake during whole-body vibration exercise: comparison with squatting as a slow voluntary movement. Eur J Appl Physiol (2001) 1.49
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast (2009) 1.47
Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A (1986) 1.46
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Sibling pair linkage and association studies between bone mineral density and the insulin-like growth factor I gene locus. J Clin Endocrinol Metab (1999) 1.45
Retracted Glucoregulation during exercise: hypoglycemia is prevented by redundant glucoregulatory systems, sympathochromaffin activation, and changes in islet hormone secretion. J Clin Invest (1986) 1.45
Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature (1982) 1.45
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int (2008) 1.44
FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab (2004) 1.43
Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J Clin Endocrinol Metab (2000) 1.43
Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports (1978) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab (2014) 1.42
Oxygen uptake in whole-body vibration exercise: influence of vibration frequency, amplitude, and external load. Int J Sports Med (2002) 1.41
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A (1988) 1.41
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc Natl Acad Sci U S A (1985) 1.39
Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women. Osteoporos Int (2002) 1.39
Dilemmas in caries diagnosis. J Am Dent Assoc (1993) 1.39
On the carcinogenicity of cadmium by the oral route. Regul Toxicol Pharmacol (1992) 1.39
Use of an internal standard to measure pyridinoline and deoxypyridinoline in urine. Clin Chem (1994) 1.38
Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. J Biol Chem (1980) 1.37
A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus. J Immunol Methods (1977) 1.36
Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int (2009) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35